🚀 Dreaming of a career where you can make a difference? Discover the endless possibilities at NIAID with our #recruitment video. Whether you’re passionate about science, administration, or innovation, there is a place for you. Learn more from some of the dedicated public servants who make NIAID a great place to work: https://lnkd.in/e-sD2kX5 #PSRW #NIAIDCareers
National Institute of Allergy and Infectious Diseases (NIAID)
Government Administration
Rockville, Maryland 42,503 followers
Join NIAID and make a difference!
About us
This is the official LinkedIn account for the National Institute of Allergy and Infectious Diseases (NIAID). NIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world. Posted comments and images do not necessarily represent the views of NIAID, NIH. Comment Policy: www.niaid.nih.gov/global/comment-policy Privacy Policy: www.niaid.nih.gov/privacy Website: www.niaid.nih.gov
- Website
-
http://www.niaid.nih.gov
External link for National Institute of Allergy and Infectious Diseases (NIAID)
- Industry
- Government Administration
- Company size
- 1,001-5,000 employees
- Headquarters
- Rockville, Maryland
- Type
- Government Agency
Locations
-
Primary
9000 Rockville Pike
Rockville, Maryland 20892, US
Employees at National Institute of Allergy and Infectious Diseases (NIAID)
-
Gail Potter
Deputy Section Chief, Clinical Trials Research Section, at National Institute of Allergy and Infectious Diseases (NIAID)
-
Rodolfo Alarcon
Program Officer at National Institutes of Health/National Institute of Allergy and Infectious Diseases
-
Dave Chen
Senior Visualization Scientist at National Institute of Allergy and Infectious Diseases (NIAID)
-
Michael Mullins
Updates
-
In 2023, NIAID hosted a workshop on “Continuing Development of Vaccines and Monoclonal Antibodies Against #Zika Virus,” in which experts from a wide array of fields convened to discuss new advances in Zika research. Although the Zika epidemic in 2015 and 2016 had devastating effects, such as microcephaly in the infants of women who became infected while pregnant, the epidemic ultimately waned before large-scale human trials of vaccines and antibody therapeutics could produce results. NIAID’s workshop allowed researchers to discuss ongoing efforts to develop vaccines and monoclonal antibodies, as well as some of the challenges which lie ahead. The workshop’s proceedings have just been published in a report in NPJ Vaccines. Learn more: https://lnkd.in/eaXKg8hU
-
#Allergy news: #NIAID-funded researchers identified a novel mechanism by which immune cells known as mast cells may protect from allergic inflammation, such as that seen in #asthma and allergic diseases. They found that mast cells use a unique pathway to reduce allergy-related inflammation in mice, and showed that this mechanism is likely similar in human allergic disease. This finding is surprising because mast cells are primarily believed to cause allergic reactions rather than protect from them. This function of mast cells could inform new approaches to treating allergy and asthma in people. The findings were published today in Immunity. Read more at https://lnkd.in/eB9msYyg Harvard Medical School Brigham and Women's Hospital
-
Using a combination of cutting-edge immunology & technologies, an HIV #vaccine concept generated immune responses that could produce multiple types of #HIV broadly neutralizing #antibodies (#bNAbs) in a NIAID-supported animal study. The results will inform the development of an HIV vaccine regimen for humans. The findings were published in Nature Immunology. Learn more: https://go.nih.gov/kytU7iT #NIH #bNAb Scripps Research IAVI
-
Antibodies produced after an initial infection with any of the four #dengue virus serotypes (DENV1-4) can either protect against or enhance the risk of developing dengue disease if a different serotype is encountered in subsequent infections. Infection with the closely related #Zika virus (ZIKV), which, like dengue, is a flavivirus transmitted by mosquitoes and which frequently co-circulates with DENV, induces antibodies that cross-react with DENV, but how ZIKV antibodies impact later dengue disease risk is not clear. In 2022, for the first time in decades, all four DENV serotypes co-circulated in Nicaragua. The recent epidemic was preceded, in 2016, by a ZIKV epidemic in that country. A new study in #ScienceTranslationalMedicine examined data collected through the long-running, #NIAID-supported Pediatric Dengue Cohort Study in Nicaragua and found that a primary infection with ZIKV increased the risk of developing symptomatic disease caused by later exposure to DENV3 or DENV4 but did not increase risk if the second exposure was to DENV1. The finding that prior ZIKV infection, like prior DENV infection, increases the risk of later symptomatic disease from certain DENV serotypes underscores the need to carefully consider flavivirus cross-reactivity when assessing vaccine safety and efficacy, the authors conclude. Learn more: https://lnkd.in/eknHDQwt
-
A drug approved to treat certain #autoimmune diseases and cancers successfully alleviated symptoms of a rare genetic syndrome called autoimmune polyendocrine syndrome type 1 (APS-1). Researchers identified the treatment based on their discovery that the syndrome is linked to elevated levels of interferon-gamma (IFN-gamma), a protein involved in #immune system responses, providing new insights into the role of IFN-gamma in #autoimmunity. The study, led by researchers at #NIAID, was published today in the New England Journal of Medicine. Learn more at https://go.nih.gov/Y8L4ADD National Human Genome Research Institute (NHGRI) National Center for Advancing Translational Sciences (NCATS) NIH Clinical Center (CC)
-
A #NIAID study derived an emergency department #syphilis screening strategy to help people get diagnosed before their infection reaches an advanced stage. Learn more: https://go.nih.gov/QlM9j0V Johns Hopkins Medicine
-
National Institute of Allergy and Infectious Diseases (NIAID) reposted this
Do you perform antimicrobial resistance (AMR) research, or would you like to join a team to work on microbial and AMR data analysis? Join NCBI & the National Institute of Allergy and Infectious Diseases (NIAID) BioIT for a virtual codeathon, Resistance is Futile: A codeathon to combat antimicrobial resistance, Sept 23-27, 2024. Apply by July 28: https://ow.ly/UgXB50RYbpe
-
Feeding children peanut products regularly from infancy to age 5 years reduced the rate of #PeanutAllergy in adolescence by 71%, even when the children ate or avoided #peanut products as desired for many years. These new findings from an #NIAID-sponsored study provide conclusive evidence that achieving long-term prevention of peanut allergy is possible through early allergen consumption. Learn more: https://go.nih.gov/1AwtQon #FoodAllergy #allergy #allergic #NIH King's College London NEJM Evidence
-
A #NIAID-supported analysis found that opportunistic infection-related hospitalizations and in-hospital mortality rates in the United States were higher among people with #HIV who had limited access to care, among other factors. The authors suggest that opportunistic infections can be prevented and their outcomes can be improved by increasing health insurance coverage, providing differentiated HIV care for certain subgroups, re-evaluating opportunistic infection prevention guidelines, and increasing the workforce of HIV specialists. Learn more: https://lnkd.in/e5HhTkkH University of Virginia